Association of soluble ST2 and infarct location within 12–24 h in STEMI: A cross-sectional study

Timothy, Sem David; Hartopo, Anggoro Budi; Anggraeni, Vita Yanti; Makrufardi, Firdian

doi:10.1016/j.amsu.2021.102844

Cited by 2 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps the release of soluble form of ST-2 by injured cardiomyocytes is what causes the concentration of sST-2 to rise in MI cases. Our results are in line with a study conducted by Zhang et al (28) who reported that serum of 59 acute MI Chinese patients had a median level of sST-2 of 2906 pg/ml. In the other hand, a study by Suryadevara et al (17) noted that the median of sST-2 in the test group was 213.46 pg/ml, while its median in the control group was 124.53 pg/ml.…”

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...supporting

confidence: 93%

“…Furthermore, Zhang et al (27) observed that serum sST-2 levels are significantly elevated early after AMI. Another study conducted by Timothy et al (28) suggested that the high sST2 levels can only be produced for a short period of time after infarct, within 12-18 hours of onset, they also studied whether the location of the infarct is associated with soluble ST2 and found that the type of infarct location had no effect on the high sST2 levels upon admission.…”

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...mentioning

confidence: 99%

“…In the current study, ROC curve was plotted to investigate the best cut-off value of 150 pg/ml of serum sST-2 that indicated the presence of MI with 86.11% sensitivity and 80.56% specificity. Also a ROC curve was done by Zhang et al (28) and determined the 36.415 ng/ml as a cut-off value for sST2, with sensitivity and specificity 77.4% and 89.7% respectively. These results indicated good validity of sST-2 as a diagnostic marker for acute MI.…”

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...mentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction

El-Hai

Nassar²,

Salem³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background:The "gold standard" approach for diagnosing myocardial infarction (MI) in patients with a high risk of the condition is cardiac troponins T or I (cTnT or cTnI), which are more accurate than CK-MB for myocardial damage. In addition to these well-known biomarkers, several intriguing biomarkers have gained attention in MI over the past few years. Soluble suppression of tumorigenicity-2 (sST-2), also known as Interleukin-1 receptor-like 1 (IL-1RL-1) is one of such biomarkers.Aim: this study aimed to assess the association of sST-2 with acute MI among Egyptian population. Patients and methods: A total of 72 individuals were enrolled in the study, including thirty-six patients with MI and thirtysix healthy normal controls. sST-2 was measured by ELISA in both groups. sST-2 was measured in patients with MI at two occasions: during first 24 hours of chest pain and 30 days after. Results: sST-2 level was higher in MI patients compared to normal controls. The level of sST-2 declined after 30 days after attack compared to day one. A positive correlation was found between serum level of sST-2 and cardiac marker of necrosis: serum CK (r = 0.65, p <0.001), CK-MB (r= 0.51, p= 0.001), and LDH (r= 057, p< 0.001). Soluble ST-2 was negatively correlated with ventricular ejection fraction (r= -0.40, p=0.015). We found that a cut-off value of 150 pg/ml for sST-2 denoted the presence of MI with 86.11% sensitivity and 80.56% specificity (p<0.001). ROC curve was plotted for serum sST-2 to indicate the development of complications after MI sets a threshold value of 3100 pg/ml with 90% sensitivity and 96.15% specificity (p<0.001). Conclusions: sST-2 is a potential biomarker for acute myocardial infarction (AMI) and possible predictors for the risk of myocardial damage in the Egyptian population.

show abstract

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...supporting

confidence: 93%

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...mentioning

confidence: 99%

Section: Assessment Of Serum Sst-2 Levels As a Potential Predictor Of...mentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction

El-Hai

Nassar²,

Salem³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…On the contrary, it was advocated that serum sST2 levels correlated with baseline infarct volume and endocardial extent of infarction. 37 A recent study by Zhang et al also proposed that sST2 could be a useful tool in the detection of atherosclerotic plaques vulnerability 38 and this correlation was further investigated by Luo et al who proposed a correlation between serum sST2 levels and the necrotic core in coronary lesions. 39 Furthermore, Van den Berg et al showed that post-ACS patients with persistently elevated sST2 concentrations are at higher risk of recurrent ACS or cardiac death during one year of follow-up.…”

Section: Introductionmentioning

confidence: 98%

Multimarkers approach in chest pain management in Emergency department: a focus on the prognostic role of sST2 and suPAR

Piccioni,

Baroni,

Scatà

et al. 2024

Emerg Care J

View full text Add to dashboard Cite

Chest pain is one of the most prevalent causes of Emergency Department (ED) admission and could be a presenting symptom of Acute Coronary Syndrome (ACS). The aim of this review was to provide an overview of the research about troponin and its limitations and new biomarkers used in patients with cardiovascular diseases, with a special focus on soluble Suppression of Tumorigenicity 2 (sST2) and Soluble Urokinase Plasminogen Activator Receptor (suPAR). In January 2024, a PubMed and Reviews in Cardiovascular Medicine (RCM) search was carried out to identify all relevant papers in the past five years. 80 articles were included in the final review. ssT2 and suPAR are involved in both acute and chronic cardiovascular disease and can predict the risk of adverse events. sST2 and suPAR are promising biomarkers that, in combination with troponin, could help in the management of patients with chest pain in the ED. Further studies are needed to validate their role in management of ACS in this specific setting.

show abstract

Association of soluble ST2 and infarct location within 12–24 h in STEMI: A cross-sectional study

Cited by 2 publications

References 22 publications

Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction

Assessment of Serum Soluble Suppression of Tumourgenicity-2 level in Patients with Acute Myocardial Infarction

Multimarkers approach in chest pain management in Emergency department: a focus on the prognostic role of sST2 and suPAR

Contact Info

Product

Resources

About